Raptor Pharmaceutical Completes Acquisition of Quinsair(TM) NOVATO, Calif., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has completed the acquisition of Quinsair™ (levofloxacin inhalation solution)...

Raptor Pharmaceutical to Participate in the Leerink Partners 4th Annual Rare Disease Roundtable NOVATO, Calif., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference: Julie Anne Smith,...

Raptor Pharmaceutical Provides Topline Results From Phase 2b CyNCh Study Evaluating RP103 in Pediatric Nonalcoholic Steatohepatitis NOVATO, Calif., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced topline results from the Phase 2b CyNCh study, which did not meet its primary endpoint of...

Raptor Pharmaceutical Receives FDA Approval of Expanded Label for PROCYSBI(R) to Treat Children Aged 2-6 Years With Nephropathic Cystinosis NOVATO, Calif., Aug. 17, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ:RPTP) today announced that the U.S. Food and Drug Administration (FDA) approved the expanded use of PROCYSBI®...